- 2022
-
Press releases - 11.02.2022
A Novel Immunotherapy Approach Redirects Epstein-Barr Antibodies toward Disease-Causing Cells
Monoclonal antibody therapy can be very effective in treating numerous illnesses, such as cancers, chronic inflammatory conditions, and infectious diseases. Researchers from Inserm, Université de Paris, Sorbonne Université and CNRS1 have designed and tested a new immunotherapy approach that uses pre-existing antibodies directed against the Epstein-Barr virus – part of the herpes family of viruses and present in over 95% of the world’s population – in order to target and destroy pathogenic (disease-causing) cells. Their findings have recently been published in a study in Science Advances.
-
Press releases - 10.02.2022
A Gene Therapy Studied in Steinert’s Disease
Myotonic dystrophy type 1 (DM1) or Steinert’s disease is a rare and debilitating genetic neuromuscular disease affecting multiple organs and with a fatal outcome. No treatment is available at present. Encouraged by previous research into its molecular causes, researchers have developed and tested a promising gene therapy that acts directly at the origin of the disease. Initial findings show correction of molecular and physiological alterations in mouse skeletal muscle1.
-
Press releases - 10.02.2022
Signature du premier contrat d’objectifs de moyens et de performance entre l’Inserm et l’État
“A new impetus for health biology research.” This is the ambition of Inserm’s Contract of Objectives, Means and Performance signed on Friday, February 4, 2022.
-
Press releases - 04.02.2022
Paris Saclay Cancer Cluster : une ambition mondiale pour l’oncologie française.
Le Paris Saclay Cancer Cluster est désormais organisé sous la forme d’une association, dont l’objet et les ambitions ont été présentés ce jour dans les locaux de Gustave Roussy, en présence d’Olivier Véran, Ministre des Solidarités et de la Santé, de Frédérique Vidal, Ministre de l’Enseignement supérieur, de la Recherche et de l’Innovation et des représentants des cinq membres fondateurs : Sanofi, Gustave Roussy, l’Inserm, l’Institut Polytechnique de Paris et l’Université Paris-Saclay.
-
Press releases - 03.02.2022
Cancer Treatment: Identification of the Blood Vessels That Allow Killer Lymphocytes to Access and Destroy Tumors
Immunotherapy, a therapeutic strategy aimed at increasing the activity of the immune system in order to recognize and destroy cancer cells, has revolutionized cancer treatment over the past decade. For the first time, the scientists were able to film the lymphocytes infiltrating the walls of the HEV vessels to enter the tumors. The likelihood of recovery of patients with metastatic melanoma (skin cancer) and treated with immunotherapy is increased when a large number of HEV vessels are present in tumors.
-
Press releases - 01.02.2022
COVID-19: A “Programmed Cell Death” Phenomenon in Hospitalized Patients
In a new study, researchers have revealed a phenomenon of programmed cell death known as “apoptosis” that would explain the loss of lymphocytes in these patients.
-
Press releases - 27.01.2022
Persistence of severe hepatic fibrosis despite substantial weight loss with bariatric surgery
A study on the effects of bariatric surgery on the severity of liver damage in patients with NASH (Non-Alcoholic Steatohepatitis or Metabolic Steatohepatitis) and severe fibrosis (bridge fibrosis or compensated cirrhosis) shows that in 50% of patients who underwent bariatric surgery, despite significant weight loss (20% to 30% of initial BMI) and improvement in metabolic risk factors (mainly type 2 diabetes), severe fibrosis persists in the medium term (5 years after surgery).
-
Press releases - 26.01.2022
Improvement in the Health of Two Infants with Severe Disharmonious Overgrowth Syndromes
A new study reports clinical, biological, and imaging improvements in two infants with severe forms of disharmonious overgrowth syndromes treated with alpelisib. These are the first data obtained on the use of this molecule in severe neonatal forms of the disease.
-
Press releases - 25.01.2022
Sickle cell disease and transfusion-dependent beta thalassemia: promising results of gene therapy treatment
Teams of researchers conducted a clinical gene therapy study consisting of transplanting in the patient’s own genetically modified hematopoietic stem cells. This phase I/II clinical trial was carried out in patients with sickle cell disease or transfusion-dependent beta thalassemia, common genetic diseases that affect red blood cells.
-
Press releases - 25.01.2022
Study of gene therapy treatment in Wiskott-Aldrich syndrome
Researchers have carried out work on treatment by gene therapy consisting of transplanting the patient’s own genetically modified hematopoietic stem cells as part of a phase I/II clinical trial in 8 patients with Wiskott-Aldrich syndrome (WAS).